Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study

201713 citationsJournal Articlediamond Open Access

Authors

Feng Zhao · University of Electronic Science and Technology of China

Wei Tian · Sichuan Provincial Hospital of Traditional Chinese Medicine

Ming Zeng · University of Electronic Science and Technology of China

Jianling Xia · University of Electronic Science and Technology of China

Honglin Hu · University of Electronic Science and Technology of China

Xinbao Hao

Liangfu Han ·

Abstract

In SBPC patients, apatinib at less than 500 mg daily dose as mono-therapy had tolerable toxicity. Apatinib at dose of 250 mg daily in combining with RT synergized pain control, the overall AEs were manageable. Further studies are needed in large sample size future trials.

Topics & Keywords

Prostate Cancer Treatment and Research Management of metastatic bone disease Hepatocellular Carcinoma Treatment and Prognosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Oncotarget

Volume 8, Issue 67, pp. 110774-110784

DOI: 10.18632/oncotarget.22719

Field-Weighted Citation Impact: 0.61